BRCA1 and ovarian carcinoma: Likewise, the NCCN guidelines endorse comprehensive genetic risk assessment, recommending both germline and somatic testing—including BRCA1-2 mutation status and HRD assessment—at diagnosis in patients with advanced ovarian cancer to determine eligibility for Poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy.